The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 19, 2015
Filed:
Oct. 09, 2013
Applicant:
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Paul E. Fleming, Wellesley, MA (US);
Geraldine C. B. Harriman, Charlestown, RI (US);
Zhan Shi, Concord, MA (US);
B. Shaowu Chen, Sudbury, MA (US);
Assignee:
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07C 213/02 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); A61K 31/18 (2006.01); A61K 31/44 (2006.01); A61K 31/4427 (2006.01); A61K 31/4965 (2006.01); A61K 31/497 (2006.01); C07C 311/21 (2006.01); C07C 311/29 (2006.01); C07C 311/44 (2006.01); C07C 311/46 (2006.01); C07C 317/34 (2006.01); C07C 323/49 (2006.01); C07D 213/46 (2006.01); C07D 213/50 (2006.01); C07D 213/65 (2006.01); C07D 213/70 (2006.01); C07D 213/71 (2006.01); C07D 213/75 (2006.01); C07D 213/76 (2006.01); C07D 213/80 (2006.01); C07D 213/89 (2006.01); C07D 237/08 (2006.01); C07D 239/26 (2006.01); C07D 239/42 (2006.01); C07D 333/34 (2006.01); C07D 333/62 (2006.01); C07D 405/06 (2006.01); C07D 409/04 (2006.01); C07D 409/06 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 513/04 (2006.01); A61K 31/50 (2006.01); A61K 31/501 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61P 1/00 (2006.01); A61P 29/00 (2006.01);
U.S. Cl.
CPC ...
C07C 311/21 (2013.01); C07C 311/29 (2013.01); C07C 311/44 (2013.01); C07C 311/46 (2013.01); C07C 317/34 (2013.01); C07C 323/49 (2013.01); C07D 213/46 (2013.01); C07D 213/50 (2013.01); C07D 213/65 (2013.01); C07D 213/70 (2013.01); C07D 213/71 (2013.01); C07D 213/75 (2013.01); C07D 213/76 (2013.01); C07D 213/80 (2013.01); C07D 213/89 (2013.01); C07D 237/08 (2013.01); C07D 239/26 (2013.01); C07D 239/42 (2013.01); C07D 333/34 (2013.01); C07D 333/62 (2013.01); C07D 405/06 (2013.01); C07D 409/04 (2013.01); C07D 409/06 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 513/04 (2013.01);
Abstract
The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.